(fluorescent adalimumab) were chosen for molecular imaging during confocal laser endomicroscopy in patients with active Crohn's disease. This study revealed that an increase of membrane-bound TNF expressing mucosal immune cells predicts response to subsequent adalimumab therapy. Conclusions: Molecular in vivo imaging is an exciting new field in patients with IBD. It is expected that this field will allow new insights into the pathophysiology of IBD and may be used for personalized medicine in the future.
Introduction
Inflammatory bowel diseases (IBDs) such as Crohn's disease and ulcerative colitis are chronic inflammatory disorders of the gut [1] [2] [3] . In these diseases, mucosal immune cells appear to be activated by the commensal microflora in a genetically susceptible host leading to uncontrolled proinflammatory cytokine production and subsequent tissue destruction [4] [5] [6] [7] [8] . Complications of IBD may comprise development of stenoses, stricture formation, abscesses, fistulas and colitis-associated colon cancer [2, 9] . Imaging of gut inflammation in IBD is essential for the diagnosis of IBD, assessment of IBD-associated complications and may help to guide optimized therapy. In particular, studies in recent years have shown that standard imaging modalities such as endoscopy, ultrasonography, CT or MRI are useful tools for the assessment of gut inflammation in IBD [10] [11] [12] [13] [14] .
Endoscopy can be used to identify inflamed regions of the bowel wall in IBD and is routinely used for the generation of biopsies from inflamed areas of the gut. Furthermore, endoscopy can be used for the assessment of mucosal healing both in patients with Crohn's disease and ulcerative colitis [15] [16] [17] [18] [19] . In addition, advanced endoscopic techniques including dye-less chromoendoscopy, capsule endoscopy and double balloon enteroscopy have been tested for the detection of IBD lesions in the small intestine [20, 21] . Finally, advanced technologies such as dye-based chromoendoscopy as well as standard endoscopy with random biopsies have been used for the detection of flat neoplasias and early cancers in the colon of IBD patients [21, 22] . Thus, endoscopy plays an important role in the management of patients with IBD and has also recently been used for imaging of inflammatory lesions in murine models of IBD [23, 24] . In addition, confocal laser endomicroscopy has been introduced as a new technique for cell imaging during ongoing endoscopy in mice and humans [25, 26] . This approach permits the analysis of single cells in the bowel wall and allows subsurface imaging of the mucosa in IBD patients [27] .
In addition to endoscopy, ultrasonography, CT and MRI are widely used for evaluation of gut inflammation in IBD [11, 12, 28, 29] . These 3 techniques have a high comparable diagnostic accuracy for the detection of lesions in IBD. Although the key limitations of ultrasonography consist of the anatomic location of the lesions and the expertise of the examiner, it should be pointed out that this technique is safe, cheap and can be repeated many times. In contrast, the key limitation of CT relates to radiation exposure of patients. Thus, this technique is usually performed in emergency situations to exclude major complications of IBD. Finally, MRI has been used for the evaluation of both the small and the large bowels in IBD patients, particularly in patients with Crohn's disease [12] . MRI permits high spatial and tissue resolution in IBD patients with no ionizing radiation. Recent studies suggest that this technique has a high diagnostic accuracy for assessing disease activity and location in these patients. In particular, MRI has been helpful in monitoring the penetrating and structuring lesions in patients with Crohn's disease [30, 31] and is now routinely performed in many centers. In addition to MRI, 18F-fluordesoxyglucose positron emission tomography has been used for the analysis of inflamed bowel segments in IBD. This technique showed promise in accurate assessment of disease compared to endoscopy but is associated with radiation [32] [33] [34] . Therefore, this technique is currently not being routinely used for the assessment of gut inflammation in IBD patients.
The above-mentioned techniques provide important insights into the anatomical segments of the gut that are affected by inflammation in IBD. However, they do not allow insights into the molecular nature of the signaling events that drive gut inflammation in these disorders. This problem may be solved by the introduction of molecular imaging in IBD patients. Molecular imaging is a technique that involves imaging of surface molecules, intracellular signaling molecules and soluble mediators such as cytokines in order to identify molecular targets for therapy or to understand molecular signaling events in vivo [35] [36] [37] . This technique is critically dependent on the availability of suitable molecular beacons or probes that can be used for in vivo imaging. Furthermore, suitable imaging devices for in vivo detection of the molecular probes are required [38] . Such molecular imaging has been widely explored in experimental animal models of gut inflammation and cancer, in vivo and ex vivo, and most molecular probes depend on fluorescein detection systems. Examples include the detection of vascular endothelial growth factor on gastrointestinal tumor cells [39] , the identification of neoplastic cells in the human colon by using a fluorescent heptapeptide [40] and the analysis of colonic neoplasias in mice by using an enzymatically activatable probe that fluoresces in the presence of the cancer-associated enzyme gamma-glutamyl transpeptidase [38] . Such imaging can be used for early diagnosis of neoplastic and inflammatory lesions in the gastrointestinal tract. Moreover, it may be used for identification of targets for therapy and optimized treatment of inflammation and cancer.
Results
The following part summarizes the current literature: Antibodies to tumor necrosis factor (anti-TNF) play a pivotal role in the treatment of IBD [2, 9, [41] [42] [43] [44] . However, their molecular mechanisms of action have only been partially characterized [45] . Clinically effective anti-TNF antibodies such as infliximab, adalimumab and golimumab bind to both soluble and membrane-bound forms of TNF and may thereby induce immunosuppression [46] [47] [48] . In particular, binding of anti-TNF antibodies appears to induce programmed cell death or apoptosis of immune cells such as T-lymphocytes by binding to membrane-bound Two recent studies have used in vivo imaging technologies to analyze the effects of anti-TNF antibodies in patients with Crohn's disease. The first study had used in vivo imaging for the detection of apoptotic immune cells in the gastrointestinal tract of patients with Crohn's disease before and after treatment with the anti-TNF antibody infliximab [49] . In this study, 14 patients with active Crohn's disease were administered with (99m)Technetium-labeled annexin V ((99m)Tc-annexin V) followed by single-photon emission CT for the detection of apoptotic cells. In anti-TNF responders, it was found that the uptake of (99m)Tc-annexin V had significantly increased in the bowel wall of patients with active Crohn's disease after treatment with infliximab. In contrast, little or no increase of uptake was observed in anti-TNF non-responders. A mean increase of 98.7% in colonic uptake of (99m)Tc-annexin V was found in anti-TNF responders as compared with 15.2% in non-responding patients suggesting that successful infliximab therapy is associated with the induction of apoptosis of mucosal immune cells. Further studies on mucosal biopsies revealed that mainly T-cells undergo apoptosis upon anti-TNF treatment and that the induction of apoptosis correlates with the clinical response to anti-TNF therapy in Crohn's disease. Collectively, these results indicated that the colonic uptake of (99m)Tc-annexin V during in vivo imaging correlates with clinical benefit of anti-TNF treatment in this disease.
The second study on anti-TNF therapy analyzed the presence of mTNF, expressing immune cells in the mucosa of 25 patients with Crohn's disease using in vivo molecular imaging [50] . This study used fluorescent adalimumab antibodies for the in vivo analysis of mTNF immune cells during ongoing endoscopy with confocal laser endomicroscopy. Topical administration of fluorescent adalimumab led to the detection of mTNF expressing immune cells in the mucosa, as shown by confocal endomicroscopy. There was a marked variability of mTNF immune cells among the individual patients, and 2 subgroups of patients with Crohn's disease (high mTNF group vs. low mTNF group) could be clearly differentiated based on quantitative image analyses. However, subsequent therapy with adalimumab subcutaneously revealed different clinical responses to anti-TNF therapy between the 2 groups. The high mTNF group showed excellent clinical responses and mucosal healing upon anti-TNF therapy, whereas the low mTNF group showed poor [47, 51] .
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Anti-TNF antibody clinical responses to adalimumab therapy. These findings suggested that the molecular imaging with fluorescent adalimumab permits prediction of clinical responses to anti-TNF therapy. However, this concept requires additional prospective studies in larger patient cohorts.
Conclusions
In summary, the current findings clearly demonstrate that in vivo imaging using molecular endoscopy has become a clinical reality for IBD patients in clinical trials.
This concept opens new avenues for optimized diagnosis and therapy of IBD. It is expected that this field will allow new insights into the pathophysiology of IBD and may be used for personalized medicine in the future by the detailed mapping of relevant immune signaling pathways in individual patients.
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